Latest News & Features
Americas
The US Food and Drug Administration will today announce that it plans to grant a Chinese-owned testing company an exclusive worldwide licence for a US government-owned patent covering a diagnostic test for the rapid detection of COVID-19. 13 November 2020
Big Pharma
The European Commission has approved a fourth contract with pharmaceutical companies Pfizer and BioNTech, following their revelation that they had developed a vaccine that could potentially prevent more than 90% of people from becoming infected by COVID-19. 12 November 2020
Americas
The US Court of Appeals for the Federal Circuit has cancelled a lower court ruling holding that a Bard patent for vascular access device was both not infringed and patent-ineligible. 12 November 2020
Americas
Allied BioScience has accused its former CEO of holding the company's IP, including inventions relating to its COVID-19 antiviral disinfectant, to ransom so he can demand an unfair amount of compensation. 12 November 2020
article
Overview of Canada’s Regulatory and Intellectual Property Regimes as they apply to Biologics and Biosimilars. The Regulatory Pathway for Marketing Approval, Data Protection, Patent Linkage and Litigation, and Current Biosimilar Approvals and Applications. A Comparison to the US and European Regimes: Differences and Similarities with Canada. 12 November 2020
Big Pharma
The US Court of Appeals for the Federal Circuit concluded that a New York judge had rushed to grant summary judgment in an inventorship dispute between Ferring and Allergan. 11 November 2020
Americas
A coronavirus vaccine unveiled by pharmaceutical companies Pfizer and BioNTech can potentially prevent more than 90% of people from getting COVID-19, it has been announced. 10 November 2020
Europe
Plausibility in the context of the inventive step and sufficiency requirements can be a contentious issue before the European Patent Office. Markus Grammel of Grünecker reports. 9 November 2020
Americas
The European Patent Office has released the long-awaited reasoning for its decision to uphold the revocation of a Broad Institute CRISPR/Cas9 patent.
In January this year, the EPO’s Board of Appeal concluded that the Broad’s patent, EP2,771,468, lacked novelty due to an invalid claim to priority.
The EPO dealt with three questions in its reasoning. 9 November 2020
Big Pharma
The US Court of Appeals for the Federal Circuit has narrowed the landscape in which patent infringement suits over generic drugs suits can be filed, in a ruling handed down yesterday, November 5. 6 November 2020